TNGX (STOCKS)
Tango Therapeutics, Inc.
$32.700000
+1.760000 (+5.69%)
Prev close: $30.940000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Malte Peters
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5,356.61M
- Employees
- 155
- P/E (TTM)
- -40.13
- P/B (TTM)
- 11.39
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
8
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.32 | $-0.32 | -0.0004 | -0.13% |
|
Dec 2025 (Q4)
|
$-0.29 | $-0.33 | +0.0364 | +11.15% |
|
Sep 2025 (Q3)
|
$0.14 | $-0.05 | +0.1938 | +360.22% |
|
Jun 2025 (Q2)
|
$-0.35 | $-0.35 | +0.0048 | +1.35% |
Financial Statements
| Revenues | $56.99M |
| Nonoperating Income/Loss | $10.27M |
| Operating Expenses | $174.52M |
| Research and Development | $129.26M |
| Other Operating Expenses | $45.26M |
| Operating Income/Loss | -$117.53M |
| Income/Loss From Continuing Operations After Tax | -$107.23M |
| Income/Loss From Continuing Operations Before Tax | -$107.26M |
| Income Tax Expense/Benefit | -$29.00K |
| Interest Income/Expense After Provision For Losses | $6.19M |
| Interest Income/Expense Operating, Net | $6.19M |
| Net Income/Loss | -$107.23M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$107.23M |
| Net Income/Loss Available To Common Stockholders, Basic | -$107.23M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$0.83 |
| Diluted Earnings Per Share | -$0.84 |
| Basic Average Shares | 370,487,987 |
| Diluted Average Shares | 377,303,716 |
| Assets | $435.79M |
| Current Assets | $392.33M |
| Cash | $379.80M |
| Other Current Assets | $12.53M |
| Noncurrent Assets | $43.47M |
| Fixed Assets | $6.38M |
| Other Non-current Assets | $37.08M |
| Liabilities | $44.29M |
| Current Liabilities | $14.33M |
| Accounts Payable | $2.43M |
| Wages | $3.24M |
| Other Current Liabilities | $8.66M |
| Noncurrent Liabilities | $29.96M |
| Equity | $391.51M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $391.51M |
| Liabilities And Equity | $435.79M |
| Net Cash Flow From Operating Activities | -$141.55M |
| Net Cash Flow From Operating Activities, Continuing | -$141.55M |
| Net Cash Flow From Investing Activities | -$61.83M |
| Net Cash Flow From Investing Activities, Continuing | -$61.83M |
| Net Cash Flow From Financing Activities | $302.34M |
| Net Cash Flow From Financing Activities, Continuing | $302.34M |
| Net Cash Flow | $98.97M |
| Net Cash Flow, Continuing | $98.97M |
| Comprehensive Income/Loss | -$107.44M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$107.54M |
| Other Comprehensive Income/Loss | $15.68M |